Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises IRLAB Therapeutics in connection with share issues
Mandate

Vinge advises IRLAB Therapeutics in connection with share issues

December 13, 2019 Capital Markets and Public M&A

Vinge advises IRLAB Therapeutics in connection with a directed share issue of SEK 70 million and a rights issue of approximately SEK 145 million.

The directed share issue was subscribed for by a number of institutional and qualified investors on the basis of an accelerated book building process. The rights issue is expected to be completed during the first quarter of 2020.

IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier Growth Market, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Stephanie Stiernstedt, Stojan Arnerstål, Anna Thoms and Maria Schultzberg.

Related

Vinge has advised Intea Fastigheter in connection with a directed share issue of approximately SEK 500 million

 Vinge has advised the property company Intea Fastigheter AB (publ) in connection with a directed share issue of shares of series D through which the company raises proceeds of approximately SEK 500 million before transaction costs. A part of the share issue is subject to subsequent approval at an extraordinary general meeting.
December 01, 2025

Vinge advises in connection with data center provider EcoDataCenter’s issue of SEK 500 million senior unsecured bonds

Vinge has advised ABG Sundal Collier in connection with EcoDC Holding AB (publ)'s issue of SEK 500 million senior unsecured bonds, within a framework of up to SEK 2 billion.
November 28, 2025

Vinge has advised Northmill Group AB in connection with the issuance of tier 2 capital bonds (T2)

 Vinge has advised Northmill Group AB in connection with its successful issuance of SEK 100 million tier 2 capital bonds (T2) with a floating rate interest of 3-month STIBOR + 650 basis points.
November 26, 2025